Loading company
$10.98-1.8%Nov 13 close
Next earnings: November 16, 2026
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
Past performance
- 1W
- -0.2%
- 1M
- -4.3%
- 3M
- -16.6%
- 6M
- -18.1%
- 1Y
- -9.0%
- 5Y
- -87.9%
$10.98-1.8%Nov 13 close
Next earnings: November 16, 2026
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
Enanta Pharmaceuticals Inc. is scheduled to report next on November 16, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $14.4M | $18.3M | -21.60% |
| Profit | -$19.5M | -$18.3M | -6.83% |
| Profit per share | -$0.67 | -$0.85 | +21.18% |
| Free Cash Flow | -$10M | $17.4M | -157.51% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“During the quarter, we continued to build momentum across both our RSV and immunology programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Enanta Pharmaceuticals Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Enanta Pharmaceuticals Inc. has no earnings call transcript available.